Recombinant Human Mediator of RNA polymerase II transcription subunit 13-like (MED13L), partial
Shipped with Ice Packs 
In Stock 
Product Specs
Form
Lyophilized powder
Note: While we prioritize shipping the format currently in stock, please specify your format preference in order remarks for customized preparation.
Note: While we prioritize shipping the format currently in stock, please specify your format preference in order remarks for customized preparation.
Lead Time
Delivery times vary depending on the purchasing method and location. Please consult your local distributor for precise delivery estimates.
Note: All proteins are shipped with standard blue ice packs unless dry ice shipping is requested in advance. Additional fees apply for dry ice shipping.
Note: All proteins are shipped with standard blue ice packs unless dry ice shipping is requested in advance. Additional fees apply for dry ice shipping.
Notes
Avoid repeated freeze-thaw cycles. Store working aliquots at 4°C for up to one week.
Reconstitution
Centrifuge the vial briefly before opening to collect the contents. Reconstitute the protein in sterile, deionized water to a concentration of 0.1-1.0 mg/mL. For long-term storage, we recommend adding 5-50% glycerol (final concentration) and aliquoting at -20°C/-80°C. Our default glycerol concentration is 50%, provided as a reference.
Shelf Life
Shelf life depends on various factors including storage conditions, buffer composition, temperature, and protein stability. Generally, liquid formulations have a 6-month shelf life at -20°C/-80°C, while lyophilized forms have a 12-month shelf life at -20°C/-80°C.
Storage Condition
Upon receipt, store at -20°C/-80°C. Aliquot for multiple uses to prevent repeated freeze-thaw cycles.
Tag Info
Tag type is determined during manufacturing.
The tag type is determined during the production process. If you require a specific tag, please inform us, and we will prioritize its development.
The tag type is determined during the production process. If you require a specific tag, please inform us, and we will prioritize its development.
Synonyms
MD13L_HUMAN; MED13L; Mediator complex subunit 13 like; Mediator complex subunit 13-like; Mediator of RNA polymerase II transcription subunit 13-like; THRAP2; Thyroid hormone receptor-associated protein 2; Thyroid hormone receptor-associated protein complex 240 kDa component-like; TRAP240L
Buffer Before Lyophilization
Tris/PBS-based buffer, 6%
Trehalose.
Datasheet
Please contact us to get it.
Protein Length
Partial
Purity
>85% (SDS-PAGE)
Species
Homo sapiens (Human)
Target Names
MED13L
Uniprot No.
Target Background
Function
Mediator complex component, a coactivator regulating transcription of nearly all RNA polymerase II-dependent genes. It acts as a bridge, conveying information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters via interactions with regulatory proteins, serving as a scaffold for preinitiation complex assembly with RNA polymerase II and general transcription factors. This subunit may specifically regulate transcription of Wnt and SHH signaling pathway targets.
Gene References Into Functions
- MED13L-related disorders represent a potential differential diagnosis for syndromic premature aging syndromes. PMID: 29159987
- MED13L truncating and missense mutations were identified in patients with facial features resembling Kleefstra syndrome, establishing it as a novel differential diagnosis. PMID: 28645799
- A new syndrome linked to deleterious MED13L variants has been described, characterized by intellectual disability, hypotonia, and congenital anomalies. Two cases involved a missense variant and a nonsense mutation in MED13L. PMID: 27500536
- Two siblings presented with an intragenic deletion (exons 3-14), causing an in-frame deletion in MED13L, inherited from their carrier mother with low-frequency mosaicism. Craniosynostosis, not previously reported in MED13L haploinsufficiency syndrome, was observed in the older sister. PMID: 28371282
- Heterozygous MED13L variants are associated with transposition of the great arteries. PMID: 25758992
- Integrated genomic data and comprehensive patient clinical evaluation may clarify the genetic heterogeneity of the MED13L haploinsufficiency phenotype. PMID: 25712080
- A meta-analysis of genome-wide association studies on blood pressure and hypertension in Chinese populations identified three new loci (CACNA1D, CYP21A2, and MED13L) and a novel variant near SLC4A7. PMID: 25249183
- MED13L haploinsufficiency impairs the development of neural crest cell-derived organs and causes intellectual disability. PMID: 25137640
- Three patients with copy number variations affecting MED13L were described, defining a recognizable MED13L haploinsufficiency syndrome. PMID: 23403903
- MED13L is crucial for Rb/E2F regulation of cell growth, complete repression of cell cycle target genes, and cell cycle inhibition. PMID: 22249253
- PROSIT240, homologous to the nuclear receptor coactivator TRAP240, is a potential component of the thyroid hormone receptor-associated protein (TRAP) complex, involved in early heart and brain development. PMID: 14638541
- High transcript abundance was observed in skeletal muscle. PMID: 15145061
Database Links
Involvement In Disease
Transposition of the great arteries dextro-looped 1 (DTGA1); Mental retardation and distinctive facial features with or without cardiac defects (MRFACD)
Protein Families
Mediator complex subunit 13 family
Subcellular Location
Nucleus.
Tissue Specificity
Highly expressed in brain (cerebellum), heart (aorta), skeletal muscle, kidney, placenta and peripheral blood leukocytes. Highly expressed in fetal brain.
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
